Westshore Wealth LLC bought a new position in Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 6,350 shares of the company’s stock, valued at approximately $926,000. Johnson & Johnson accounts for approximately 1.0% of Westshore Wealth LLC’s holdings, making the stock its 13th biggest position.
Several other hedge funds also recently bought and sold shares of JNJ. Ilmarinen Mutual Pension Insurance Co bought a new position in Johnson & Johnson during the 3rd quarter worth $31,646,000. UMA Financial Services Inc. bought a new position in shares of Johnson & Johnson in the third quarter worth $431,000. Voya Financial Advisors Inc. grew its position in Johnson & Johnson by 0.5% in the third quarter. Voya Financial Advisors Inc. now owns 78,872 shares of the company’s stock valued at $10,143,000 after acquiring an additional 387 shares during the last quarter. Endurant Capital Management LP bought a new position in Johnson & Johnson in the third quarter valued at about $13,897,000. Finally, Merit Financial Group LLC grew its position in Johnson & Johnson by 5.2% in the third quarter. Merit Financial Group LLC now owns 8,633 shares of the company’s stock valued at $1,117,000 after acquiring an additional 427 shares during the last quarter. Institutional investors and hedge funds own 69.30% of the company’s stock.
In related news, COO Michael E. Sneed sold 58,128 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $149.39, for a total transaction of $8,683,741.92. Following the completion of the sale, the chief operating officer now owns 107,511 shares in the company, valued at $16,061,068.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director William D. Perez purchased 500 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were bought at an average price of $127.69 per share, with a total value of $63,845.00. Following the acquisition, the director now directly owns 16,030 shares of the company’s stock, valued at approximately $2,046,870.70. The disclosure for this purchase can be found here. Corporate insiders own 0.27% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $1.88 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.01. The firm had revenue of $20.75 billion during the quarter, compared to the consensus estimate of $20.83 billion. Johnson & Johnson had a return on equity of 39.27% and a net margin of 22.18%. The company’s quarterly revenue was up 1.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.97 earnings per share. As a group, equities research analysts forecast that Johnson & Johnson will post 9.03 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th were issued a dividend of $0.95 per share. The ex-dividend date was Monday, February 24th. This represents a $3.80 annualized dividend and a yield of 2.88%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 43.78%.
A number of research analysts have issued reports on the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $168.00 target price on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Barclays upgraded Johnson & Johnson from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $140.00 to $173.00 in a research report on Thursday, December 19th. Argus reiterated a “buy” rating and issued a $155.00 target price (down previously from $165.00) on shares of Johnson & Johnson in a research report on Friday. Wells Fargo & Co lifted their price target on Johnson & Johnson from $155.00 to $165.00 and gave the company an “overweight” rating in a research note on Thursday, January 9th. Finally, Citigroup cut their price objective on Johnson & Johnson from $163.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Johnson & Johnson has an average rating of “Buy” and a consensus price target of $160.00.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Outstanding Shares and The Effect on Share Price
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.